Published in Cancer on March 01, 2004
Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol (2009) 2.11
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48
Late local recurrence of dermatofibrosarcoma protuberans in the skin of female breast. World J Surg Oncol (2010) 1.43
Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency. J Allergy Clin Immunol (2011) 1.08
Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans. Sarcoma (2011) 1.01
Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol (2010) 0.97
Painful late recurrence of dermatofibrosarcoma protuberans of breast in a centurian female. J Clin Diagn Res (2013) 0.87
Dermatofibrosarcoma protuberans: from translocation to targeted therapy. Cancer Biol Med (2015) 0.82
Dermatofibrosarcoma protuberans: a case report. Case Rep Dermatol (2014) 0.80
Fibrosarcomatous change in the background of dermatofibrosarcoma protuberans in male breast: Study of a rare case and review of the entity. J Midlife Health (2016) 0.79
Dermatofibrosarcoma Protuberans: Insights into a Rare Soft Tissue Tumor. J Clin Imaging Sci (2016) 0.79
Dermatofibrosarcoma Protuberans: A Rare Malignancy of the Breast. Oman Med J (2015) 0.78
Dermatofibrosarcoma protuberans: a study of clinical, pathologic, genetic, and therapeutic features in Korean patients. Yonsei Med J (2015) 0.77
Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report. Oral Maxillofac Surg (2008) 0.76
Clinicopathological features of dermatofibrosarcoma protuberans. Oncol Lett (2015) 0.75
A single-institutional review of 68 patients with dermatofibrosarcoma protuberans: wide re-excision after inadequate previous surgery results in a high rate of local control. World J Surg Oncol (2017) 0.75
Dermatofibrosarcoma Protu-Berans with Lung Metastasis Requiring Pneumonectomy. Rare Tumors (2015) 0.75
A malignant neoplasm imitating a subcutaneous cyst. Eplasty (2012) 0.75
Surgical Treatment of Dermatofibrosarcoma Protuberans Using a Reversed Adipofascial Sural Flap - Case Report. Clujul Med (2014) 0.75
Dermatofibrosarcoma protuberans of penis: Case report and literature review. Urol Ann (2014) 0.75
Dermatofibrosarcoma Protuberans. Curr Treat Options Oncol (2017) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell (2010) 3.70
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol (2002) 3.05
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Melanoma information on the Internet: often incomplete--a public health opportunity? J Clin Oncol (2002) 2.61
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol (2004) 2.42
Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol (2002) 2.35
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer (2003) 2.23
The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol (2005) 2.12
Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol (2008) 2.11
Electrosurgery and implantable electronic devices: review and implications for office-based procedures. Dermatol Surg (2011) 2.07
Atypical Spitz Tumors: A Diagnostic Challenge. Arch Pathol Lab Med (2015) 2.03
Chemotherapy for metastatic melanoma: time for a change? Cancer (2007) 1.99
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92
BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res (2006) 1.85
Connective tissue remodeling induced by carbon dioxide laser resurfacing of photodamaged human skin. Arch Dermatol (2004) 1.85
The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer (2009) 1.85
Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer (2007) 1.83
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol (2011) 1.75
The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO J (2003) 1.72
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother (2012) 1.68
Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol (2005) 1.68
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66
The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer (2007) 1.64
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol (2008) 1.61
Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg (2004) 1.58
Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol (2002) 1.57
Multimodality management of desmoid tumors: how important is a negative surgical margin? J Surg Oncol (2008) 1.55
Interferon alfa-2a for melanoma metastases. Lancet (2002) 1.55
Treatment of acne vulgaris with a pulsed dye laser: a randomized controlled trial. JAMA (2004) 1.49
Melanoma--an unlikely poster child for personalized cancer therapy. N Engl J Med (2010) 1.47
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell (2008) 1.46
Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist (2003) 1.42
Proper margins of excision in dermatofibrosarcoma protuberans: wide or narrow? Ann Surg Oncol (2008) 1.42
Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res (2008) 1.41
Melanoma in middle-aged and older men: a multi-institutional survey study of factors related to tumor thickness. Arch Dermatol (2009) 1.39
Malignant melanoma arising in the setting of epidermolysis bullosa simplex: an important distinction from epidermolysis bullosa nevus. JAMA Dermatol (2013) 1.39
Lymphangiogenesis: host and tumor factors in nodal metastasis. Arch Dermatol (2008) 1.38
Prevalence of psychotropic medication use among cosmetic and medical dermatology patients: a comparative study. J Am Acad Dermatol (2006) 1.38
Atypical fibroxanthoma with lymphomatoid reaction. J Cutan Pathol (2010) 1.38
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36
Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol (2011) 1.35
Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma. Cancer (2003) 1.35
Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol (2010) 1.35
CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol (2008) 1.28
Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer (2003) 1.24
Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer (2013) 1.23
Ipilimumab. Nat Rev Drug Discov (2011) 1.20
Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci Transl Med (2012) 1.18
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys (2011) 1.17
Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol (2011) 1.16
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood (2014) 1.16
Dissecting the oncogenic potential of Gli2: deletion of an NH(2)-terminal fragment alters skin tumor phenotype. Cancer Res (2002) 1.15
Sentinel Lymph Node Biopsy Use Among Melanoma Patients 75 Years of Age and Older. Ann Surg Oncol (2015) 1.15
Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control (2009) 1.15
Distinct gene expression profiles of viral- and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis. J Invest Dermatol (2012) 1.14
Behavioral determinants of successful early melanoma detection: role of self and physician skin examination. Cancer (2011) 1.14
Efficacy of skin self-examination practices for early melanoma detection. Cancer Epidemiol Biomarkers Prev (2009) 1.12
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12
Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin. Am J Pathol (2007) 1.11
Conjunctival melanomas harbor BRAF and NRAS mutations--Letter. Clin Cancer Res (2013) 1.10
Retroperitoneal sarcomas. Cancer Imaging (2005) 1.09
Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol (2013) 1.09
c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol (2009) 1.08
Vulvar melanoma: a report of 20 cases and review of the literature. J Am Acad Dermatol (2004) 1.08
Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys (2007) 1.07
A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol (2011) 1.06
Point: Interferon-alpha for adjuvant therapy for melanoma patients. J Natl Compr Canc Netw (2004) 1.06
An education theory-based method to teach a procedural skill. Arch Dermatol (2004) 1.04
Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev (2012) 1.04
Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. Ann Surg Oncol (2009) 1.04
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res (2012) 1.04
Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer (2003) 1.03